BSG and hepatocellular carcinoma: In addition to the small-molecule compound targeting CD147, the anti-CD147 drug metuximab (Licartin) prevents tumor recurrence after orthotopic liver transplantation or percutaneous radiofrequency ablation in patients with advanced hepatocellular carcinoma [103,104].